WO2013021962A1 - Kit de diagnostic de la maladie d'alzheimer par mesure de chaînes d'hydrates de carbone d'une protéine du complément c3, marqueur de diagnostic et procédé de détection - Google Patents

Kit de diagnostic de la maladie d'alzheimer par mesure de chaînes d'hydrates de carbone d'une protéine du complément c3, marqueur de diagnostic et procédé de détection Download PDF

Info

Publication number
WO2013021962A1
WO2013021962A1 PCT/JP2012/069957 JP2012069957W WO2013021962A1 WO 2013021962 A1 WO2013021962 A1 WO 2013021962A1 JP 2012069957 W JP2012069957 W JP 2012069957W WO 2013021962 A1 WO2013021962 A1 WO 2013021962A1
Authority
WO
WIPO (PCT)
Prior art keywords
amount
sugar chain
disease
alzheimer
protein
Prior art date
Application number
PCT/JP2012/069957
Other languages
English (en)
Japanese (ja)
Inventor
克哉 浦上
美也子 木村
Original Assignee
国立大学法人鳥取大学
株式会社ハイパーブレイン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立大学法人鳥取大学, 株式会社ハイパーブレイン filed Critical 国立大学法人鳥取大学
Priority to JP2013528019A priority Critical patent/JP5892169B2/ja
Publication of WO2013021962A1 publication Critical patent/WO2013021962A1/fr

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Definitions

  • the lectin used in the embodiment of the present invention is not particularly limited as long as it is a lectin that is WGA-binding and recognizes a ConA-binding sugar chain.
  • lectins that recognize mannose include Canavalia ensiformis agglutinin (ConA), Lens inaculinaris agglutinin (LCA), Pisum sativum agglutinin (PSA), Bowringia milbraedii agglutinin (BMA), Dolichos lablab agglutinin (DLA), ), Gerardia savaglia lectin (GSL), Machaerium biovulatum agglutinin (MBA), Macharium lunatus agglutinin (MLA), Narcissus pseudonarcissus agglutinin (NPA), Epipactis helleborine agglutinin (EHA), L , Narcissus lobularis agglutinin (NLA),
  • a sugar chain-recognizing monoclonal antibody for example, a sugar chain or a part thereof, a complement C3 protein to which a sugar chain is added or a partial peptide thereof, or a complex of these and another carrier molecule or carrier protein is used.
  • Immunize a warm-blooded animal collect spleen cells, lymph node cells, B lymphocytes, etc. from the immunized animal, and obtain a hybridoma that produces a monoclonal antibody by cell fusion of the obtained cells with a myeloma cell line, It can be produced by isolating a monoclonal antibody from the hybridoma.
  • CSF was collected from 93 patients by lumbar puncture, and blood was collected from 89 patients and immediately stored at -80 ° C.
  • CSF and blood data were different, and in the AD group, CSF and blood data were from the same patient. There was no significant difference between the two groups according to age.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

[Problème] L'invention concerne la détection précoce de la maladie d'Alzheimer. [Solution] L'invention concerne un kit de diagnostic destiné à diagnostiquer la maladie d'Alzheimer, ledit kit de diagnostic comportant un moyen de détection de chaînes d'hydrates de carbone servant à détecter quantitativement la quantité de chaînes d'hydrates de carbone issues d'une protéine du complément C3 dans un échantillon de fluide corporel d'un mammifère à tester. L'invention concerne également un marqueur de diagnostic destiné à diagnostiquer la maladie d'Alzheimer, le marqueur de diagnostic comprenant la quantité de chaînes d'hydrates de carbone issues de la protéine du complément C3 dans un échantillon de fluide corporel d'un mammifère à tester. L'invention concerne en outre un procédé de détection d'un indicateur de morbidité de la maladie d'Alzheimer, le procédé de détection comportant une étape consistant à détecter quantitativement la quantité de chaînes d'hydrates de carbone issues de la protéine du complément C3 dans un échantillon de fluide corporel d'un mammifère à tester.
PCT/JP2012/069957 2011-08-09 2012-08-06 Kit de diagnostic de la maladie d'alzheimer par mesure de chaînes d'hydrates de carbone d'une protéine du complément c3, marqueur de diagnostic et procédé de détection WO2013021962A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013528019A JP5892169B2 (ja) 2011-08-09 2012-08-06 補体ｃ３タンパク質の糖鎖測定によるアルツハイマー型認知症の診断キット、診断マーカー及び検出方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011-173946 2011-08-09
JP2011173946 2011-08-09

Publications (1)

Publication Number Publication Date
WO2013021962A1 true WO2013021962A1 (fr) 2013-02-14

Family

ID=47668469

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/069957 WO2013021962A1 (fr) 2011-08-09 2012-08-06 Kit de diagnostic de la maladie d'alzheimer par mesure de chaînes d'hydrates de carbone d'une protéine du complément c3, marqueur de diagnostic et procédé de détection

Country Status (3)

Country Link
JP (1) JP5892169B2 (fr)
TW (1) TWI542877B (fr)
WO (1) WO2013021962A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021045061A1 (fr) * 2019-09-02 2021-03-11 富士レビオ株式会社 Procédé pour mesurer une substance associée à la lectine, kit pour mesurer une substance associée à la lectine, et lectine marquée bloquée utilisée dans celui-ci
WO2021045065A1 (fr) * 2019-09-02 2021-03-11 富士レビオ株式会社 Méthode de mesure d'une substance de liaison à la lectine, kit de mesure d'une substance de liaison à la lectine et support de capture à utiliser dans cette dernière
CN113311056A (zh) * 2021-05-10 2021-08-27 中国医学科学院北京协和医院 用于遗传性血管水肿的标志物及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5207469B2 (ja) * 2006-09-06 2013-06-12 国立大学法人鳥取大学 アルツハイマーの診断キット、診断マーカー及び病態指標の検出方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LAURA VERGA: "Alzheimer patients and Down patients: cerebral preamyloid deposits differ ultrastructurally and histochemically from the amyloid of senile plaques", NEUROSCIENCE LETTERS, vol. 105, no. ISS.3, 1989, pages 294 - 299 *
MIYAKO TANIGUCHI: "Alzheimer-byo Shinki Shindan Marker to shite no To Tanpakushitsu", JAPANESE JOURNAL OF GERIATRICS, vol. 44, no. IS.40, 20 May 2007 (2007-05-20) *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021045061A1 (fr) * 2019-09-02 2021-03-11 富士レビオ株式会社 Procédé pour mesurer une substance associée à la lectine, kit pour mesurer une substance associée à la lectine, et lectine marquée bloquée utilisée dans celui-ci
WO2021045065A1 (fr) * 2019-09-02 2021-03-11 富士レビオ株式会社 Méthode de mesure d'une substance de liaison à la lectine, kit de mesure d'une substance de liaison à la lectine et support de capture à utiliser dans cette dernière
US20220326245A1 (en) * 2019-09-02 2022-10-13 Fujirebio Inc. Lectin-binding substance measurement method, lectin-binding substance measurement kit, and blocked labeled lectin for use in these
US11988666B2 (en) 2019-09-02 2024-05-21 Fujirebio Inc. Lectin-binding substance measurement method, lectin-binding substance measurement kit, and blocked labeled lectin for use in these
CN113311056A (zh) * 2021-05-10 2021-08-27 中国医学科学院北京协和医院 用于遗传性血管水肿的标志物及其应用

Also Published As

Publication number Publication date
TWI542877B (zh) 2016-07-21
JPWO2013021962A1 (ja) 2015-03-05
JP5892169B2 (ja) 2016-03-23
TW201314207A (zh) 2013-04-01

Similar Documents

Publication Publication Date Title
JP5207469B2 (ja) アルツハイマーの診断キット、診断マーカー及び病態指標の検出方法
CN104777308B (zh) 先兆子痫检测和治疗的方法和组合物
KR101531949B1 (ko) 아밀로이드 베타 펩티드의 개선된 검출 방법 및 시약
US20110166035A1 (en) Novel diagnostic method
JP7457337B2 (ja) アルツハイマー病バイオマーカー
WO2014025013A1 (fr) Procédé de détection de glycoforme et dispositif de détection de glycoforme
US8609346B2 (en) Method for diagnosing alzheimer's disease using serum glycoprotein as biomarker
US7771957B2 (en) Method for diagnosing alzheimer's disease
JP2024019509A (ja) アルツハイマー病又は発症前アルツハイマー病の診断用マーカー及び診断用キット、脳内へのアミロイドβタンパク質の蓄積量の評価方法、並びに被験者におけるアルツハイマー病又は発症前アルツハイマー病の検出を補助するためのインビトロの方法
EP3457133A1 (fr) Marquer diagnostique de la démence et procédé d'identification de la survenance de la démence à l'aide dudit marqueur
JP5892169B2 (ja) 補体ｃ３タンパク質の糖鎖測定によるアルツハイマー型認知症の診断キット、診断マーカー及び検出方法
JP7186173B2 (ja) 神経変性疾患を発症するリスクがある個体を検出する方法
JP6262727B2 (ja) アルツハイマー病及び軽度認知障害関連トロポミオシンアイソフォーム
EP2646462B1 (fr) Méthodes et compositions de contrôle de l'activité phagocytaire
WO2020255938A1 (fr) Marqueur de diagnostic pour trouble cognitif léger
US20220260593A1 (en) Targets and methods of diagnosing, monitoring and treating frontotemporal dementia
WO2009051599A1 (fr) Utilisation de biomarqueurs de la maladie d'alzheimer pour des tests de diagnostic et pour le criblage de médicaments
WO2022070798A1 (fr) Marqueurs combinés pour différencier des états pathologiques de la maladie d'alzheimer et procédé de différenciation d'états pathologiques de la maladie d'alzheimer les utilisant
EP2924437B1 (fr) Méthode de détection de maladie neurologique accompagnée d'une inflammation et/ou d'une démyélinisation
EP1772733A1 (fr) Méthode de diagnostic différential et surveillance de la démence de type Alzheimer
JP2014070037A (ja) アルツハイマー病の診断薬および診断方法
JP2005145837A (ja) アルツハイマー病の診断方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12822796

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2013528019

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12822796

Country of ref document: EP

Kind code of ref document: A1